• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在不同社区流行率和疫苗接种率下,五家医院在住院第二天后重复检测严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)聚合酶链反应(PCR)检测的获益和成本。

Benefit and cost of repeating a severe acute respiratory coronavirus virus 2 (SARS-CoV-2) polymerase chain reaction (PCR) test after the second day of hospitalization in five hospitals during various community prevalences and vaccination rates.

机构信息

Medicine Department, Rochester Regional Health, Rochester, New York.

Quality and Safety Department, Rochester Regional Health, Rochester, New York.

出版信息

Infect Control Hosp Epidemiol. 2023 Jan;44(1):106-109. doi: 10.1017/ice.2022.157. Epub 2022 Jun 16.

DOI:10.1017/ice.2022.157
PMID:35705231
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9237495/
Abstract

At our hospital, universal severe acute respiratory coronavirus virus 2 (SARS-CoV-2) polymerase chain reaction (PCR) testing was performed upon admission and again after 2 inpatient days. As community-wide prevalence, admission, and vaccination rates varied, the number needed to benefit fluctuated between 16 and 769 and the cost per additional detection fluctuated between $800 and $29,400. These 2 metrics were negatively associated with new hospital admissions. No other community indicator was associated with the number needed to benefit and cost per additional detection.

摘要

在我们医院,所有入院患者均行严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)聚合酶链反应(PCR)检测,且在入院后第 2 天再次检测。由于社区流行率、入院率和疫苗接种率存在差异,因此获益人数需要数在 16 至 769 人之间波动,额外检测的成本在 800 美元至 29400 美元之间波动。这两个指标与新入院人数呈负相关。其他社区指标与获益人数和额外检测成本无关。

相似文献

1
Benefit and cost of repeating a severe acute respiratory coronavirus virus 2 (SARS-CoV-2) polymerase chain reaction (PCR) test after the second day of hospitalization in five hospitals during various community prevalences and vaccination rates.在不同社区流行率和疫苗接种率下,五家医院在住院第二天后重复检测严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)聚合酶链反应(PCR)检测的获益和成本。
Infect Control Hosp Epidemiol. 2023 Jan;44(1):106-109. doi: 10.1017/ice.2022.157. Epub 2022 Jun 16.
2
Incidence of Positive Severe Acute Respiratory Syndrome Coronavirus Polymerase Chain Reaction After Coronavirus Disease 2019 Vaccination With up to 8 Months of Follow-up: Real-life Data From the Capital Region of Denmark.新冠肺炎疫苗接种后长达 8 个月的随访中聚合酶链反应检测 SARS-CoV-2 呈阳性的发生率:来自丹麦首都大区的真实数据。
Clin Infect Dis. 2022 Aug 24;75(1):e675-e682. doi: 10.1093/cid/ciac012.
3
Universal testing for severe acute respiratory syndrome coronavirus 2 in 2 Philadelphia hospitals: carrier prevalence and symptom development over 2 weeks.在费城的 2 家医院进行的严重急性呼吸综合征冠状病毒 2 通用检测:2 周内的携带者流行率和症状发展。
Am J Obstet Gynecol MFM. 2020 Nov;2(4):100226. doi: 10.1016/j.ajogmf.2020.100226. Epub 2020 Sep 11.
4
Polymerase-chain reaction testing to prevent hospital-acquired severe acute respiratory syndrome coronavirus 2 infection in Shinjuku, an epicenter in Tokyo: The Tokyo Women's Medical University model.聚合酶链式反应检测预防东京新宿医院获得性严重急性呼吸综合征冠状病毒 2 感染:东京女子医科大学模式。
Respir Investig. 2021 May;59(3):356-359. doi: 10.1016/j.resinv.2020.12.009. Epub 2021 Jan 26.
5
Universal admission testing with a rapid molecular point-of-care test and real-time polymerase chain reaction (PCR) assay for the detection of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): Comparative performance and infection prevention implications.
Infect Control Hosp Epidemiol. 2023 Jan;44(1):138-140. doi: 10.1017/ice.2022.244. Epub 2022 Oct 18.
6
Initial and 5-day positivity rate of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) polymerase chain reaction (PCR) in exposed inpatients within shared rooms during the omicron-variant dominant period.奥密克戎变异株流行期间,同住暴露患者 5 天内 SARS-CoV-2 核酸 PCR 阳性率
Infect Control Hosp Epidemiol. 2024 Mar;45(3):377-379. doi: 10.1017/ice.2023.230. Epub 2023 Oct 23.
7
Universal Polymerase Chain Reaction Screening for Severe Acute Respiratory Syndrome Coronavirus 2 in Asymptomatic Patients Before Hospital Admission in Tokyo, Japan.日本东京无症状住院患者的严重急性呼吸综合征冠状病毒 2 的通用聚合酶链反应筛查。
J Clin Virol. 2021 Sep;142:104915. doi: 10.1016/j.jcv.2021.104915. Epub 2021 Jul 15.
8
Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.在普通人群中进行 SARS-CoV-2 监测的四种不同策略的有效性和成本效益(CoV-Surv 研究):一项关于集群随机、双因素对照试验的研究方案的结构化总结。
Trials. 2021 Jan 8;22(1):39. doi: 10.1186/s13063-020-04982-z.
9
Asymptomatic Testing of Hospital Admissions for SARS-CoV-2: Is it OK to Stop?对医院收治的新冠病毒患者进行无症状检测:可以停止吗?
Clin Infect Dis. 2024 Feb 17;78(2):356-360. doi: 10.1093/cid/ciad423.
10
Comprehensive Characterization of COVID-19 Patients with Repeatedly Positive SARS-CoV-2 Tests Using a Large U.S. Electronic Health Record Database.利用美国大型电子健康记录数据库对反复 SARS-CoV-2 检测呈阳性的 COVID-19 患者进行全面特征描述。
Microbiol Spectr. 2021 Sep 3;9(1):e0032721. doi: 10.1128/Spectrum.00327-21. Epub 2021 Aug 18.